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Abstract Two high Mr protein bands (440 and 420 kDa) in
sheep brain microsomal membranes were labeled with the
photoaffinity ATP analog, O-(4-benzoyl)benzoyl adenosine 5P-
triphosphate (Bz2ATP). The 420 kDa band is labeled by [K-32P]-
Bz2ATP with about 1000-fold higher affinity than the 440 kDa
band. The heavily labeled 420 kDa band is identified as dynein
heavy chain based on its partial amino acid sequence, and cross-
reactivity with anti-dynein antibodies. The 440 kDa protein is
immunologically identified as the type-2 RyR. Bz2ATP binding
is obtained in the absence of divalent cations. Bz2ATP and ATP
increased the binding of ryanodine to its receptor up to 3-fold,
and increased the binding affinity up to 6-fold. Other nucleotides
stimulate ryanodine binding with decreasing effectiveness :
Bz2ATPsATPsADPsAMPsAMP-PNPsGTPs cAM-
P. With respect to nucleotide specificity, this binding site is
similar to the skeletal muscle RyR (type 1). However, the brain
RyR may have additional one or more sites with lower affinity
with inhibitory effect on ryanodine binding. These results suggest
that the major RyR isoform in sheep brain corresponds to the
type-2 isoform, and that modulation of ryanodine binding by
ATP involves its binding to the RyR protein. The association of
dynein with brain microsomal membranes may reflect a linkage
of RyR to the cytoskeleton.
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1. Introduction
The concentration of intracellular free Ca2 plays an im-
portant role in the regulation of cell function in both contrac-
tile and non-contractile cells [1]. The endoplasmic reticulum
(ER) contains two well characterized Ca2-release channels,
the InsP3 receptor and the ryanodine receptor (RyR) [2^7],
and less well characterized channels including a voltage-sensi-
tive cation channel that is also highly permeable to Ca2 [8].
RyR proteins, originally puri¢ed from skeletal and cardiac
muscle SR (as type-1 and type-2 receptors, respectively), com-
prise large homotetramers with an apparent subunit Mr of
V450 kDa on SDS-PAGE (reviewed in [9]). In practice,
they show anomalously fast mobility in SDS-PAGE: the
ryr1 cDNA cloned from rabbit skeletal muscle encodes a
RyR predicted to have a subunit molecular mass of 565
kDa [4,5], while the ryr2 cDNA corresponding to the rabbit
cardiac muscle type-2 RyR corresponds to a protein of 566
kDa [6,7]. The amino acid sequence of a ‘type-3’ RyR was
¢rst deduced from rabbit brain cDNA [13]. It has a predicted
mass of 552 kDa, slightly lower than that of the skeletal and
cardiac RyRs.
It is now clear that all three major isoforms are widely
distributed in di¡erent mammalian tissues, so that while,
quantitatively, the major mammalian brain isoform generally
appears to be the type-2 RyR, other proteins are also present
[9]. RyRs are also present in mammalian brain [10^13], liver
[14] and smooth muscle [15,16].
The function of RyR proteins, including those in brain ER,
is modulated by endogenous Ca2, Mg2 and adenine nucleo-
tides (reviewed in [9]). The RyR amino acid sequence contains
at least twice the ATP binding consensus sequence [4]. How-
ever, their exact location is unknown. Using the photoreactive
ATP analog, Bz2ATP, the ATP binding site(s) of the skeletal
muscle RyR were localized to 27 kDa and 13 kDa proteolytic
fragments derived from the C-terminal of the molecule [17]. In
brain microsomes, ATP was found to stimulate ryanodine
binding at concentrations below 1 mM and to inhibit at high-
er concentrations [11,18], suggesting the involvement of two
or more di¡erent binding sites. In this study, we demonstrate
that the major sheep brain RyR is the type-2 isoform, and
characterized its nucleotide binding sites. We also identify
dynein heavy chain as a major ATP binding protein in ER
microsomal membranes.
2. Materials and methods
2.1. Materials
ATP, EGTA, EDTA, Tris, MOPS, AMP, ADP, AMP-PNP, GTP,
cAMP, Caps, were obtained from Sigma. Benzoyl-benzoyl-ATP
(Bz2ATP) and [K-32P]-Bz2ATP were synthesized and puri¢ed as de-
scribed by Williams and Coleman [19] with some modi¢cations to
scale down. Brie£y, ATP concentration was 0.55 mM, 1,1P-carbon-
yldiimidazole (CDI) and benzoyl-benzoic acid ratio was 2.2 and the
acetone extraction step was omitted. [K-32P]-ATP was obtained from
Amersham, and [3H]ryanodine (60 Ci/mmol) was purchased from
New England Nuclear. Unlabeled ryanodine was obtained from Cal-
biochem. Monoclonal anti-RyR was kindly provided by Campbell
[20], and a rabbit anti-cardiac RyR polyclonal antiserum was kindly
provided by S. Fleischer. An anti-dynein antibody was obtained from
Sigma, and horseradish peroxidase (HRP)-conjugated anti-mouse,
and HRP-conjugated anti-rabbit antibodies were from Promega.
2.2. Membrane preparations
A crude synaptosomal fraction was prepared from whole sheep
brain essentially as described previously [21]. Crude microsomes
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were further puri¢ed by sucrose gradient centrifugation and the mem-
branes were frozen in liquid nitrogen, and stored at 370‡C. In most
experiments the membranes at the 1.0/1.2 M sucrose interface were
used. Junctional SR membranes were prepared from rabbit fast twitch
skeletal muscle as described by Saito et al. [22]. Sheep cardiac SR
membranes were prepared by the method of Chamberlain et al. [23].
Protein concentrations were determined by the standard Lowry pro-
cedure [24].
2.3. [3H]ryanodine binding
Unless otherwise speci¢ed, brain microsomal membranes were in-
cubated for 1^2 h at 37‡C in a standard binding solution containing
0.5 or 1 M NaCl, 20 mM MOPS (pH 7.4), 50 WM free [Ca2] and 5 to
20 nM [3H]ryanodine. Unbound ryanodine was separated from pro-
tein bound ryanodine by sample ¢ltration through Whatman GF/C
¢lters, followed by three washes with 4 ml ice-cold bu¡er containing
0.2 M NaCl, 10 mM MOPS (pH 7.4) and 50 WM CaCl2. The retained
radioactivity in the dried ¢lters was determined by liquid scintillation
counting technique. Speci¢c binding of [3H]ryanodine is de¢ned as the
di¡erence between the binding in the absence and the presence of
100 WM unlabeled ryanodine.
2.4. Photoa⁄nity labeling of ATP binding proteins by
[K-32P]-Bz2ATP
Brain microsomal membranes (1 mg/ml) were irradiated with UV
light for 3^4 min in the presence of 1 nM to 5 WM of [K-32P]-Bz2ATP
(4U106 to 107 cpm/nmol) in 50 Wl of 20 mM MOPS (pH 7.4) and 0.4
M NaCl, and other reagents as indicated in the ¢gure and table
legends. The irradiated membranes were immediately diluted 1:1
with a bu¡er containing 125 mM Tris-HCl (pH 6.8), 20% (v/v) glyc-
erol, 4% (w/v) SDS and 2% (v/v) 2-mercaptoethanol, and incubated
for 3 min at 90‡C. The samples were analyzed by SDS-PAGE as
described below. Autoradiography of the dried gels was carried out
using Kodak X-Omat ¢lm. Quantitative analysis of the labeled pro-
tein bands was determined by densitometric scanning using a Molec-
ular Dynamics personal densitometer, using the Image Quant soft-
ware provided by the manufacturer. Band densities were con¢rmed
to be linearly related to ¢lm exposure times over the periods chosen
for analysis.
2.5. Gel electrophoresis and immunoblot analysis
Analysis of protein pro¢les by SDS polyacrylamide slab gel electro-
phoresis (SDS-PAGE) was performed using the discontinuous bu¡er
system of Laemmli [25] in 1.5 mm thick slab gels containing a gradient
of 3.5^6% (w/v) acrylamide. Gels were stained with Coomassie blue.
The molecular mass standards were: myosin (200 kDa); L-galactosi-
dase (116 kDa); phosphorylase b (97.4 kDa); bovine serum albumin
(66.2 kDa) and ovalbumin (42.7 kDa), (Bio-Rad), and cross-linked
phosphorylase b (97 to 873 kDa, monomer to octamer, Sigma). The
separated proteins were electrophoretically transferred onto nitrocel-
lulose membranes using either Tris/glycine (pH 8.3) [26] or 20 mM
Caps bu¡er containing 0.01% (w/v) SDS (pH 10.5). The membranes
were blocked with 5% (w/v) non-fat dry milk and 0.1% (v/v) Tween-20
in 10 mM Tris-HCl, pH 7.8 and 0.15 M NaCl. The membranes were
then incubated with anti-skeletal muscle RyR, anti-cardiac RyR or
anti-dynein antibodies, and then with horseradish peroxidase (HRP)-
conjugated anti-mouse or HRP-conjugated anti-rabbit antibodies.
Antibody detection was carried out using enhanced chemilumines-
cence.
2.6. Internal amino acid sequence analysis
Brie£y, brain microsomes were separated by SDS-PAGE (3^6%
acrylamide) and the 420 kDa protein bands were cut out of the gel,
digested by endoproteinase Lys C. The resulting peptides were sepa-
rated by reverse phase HPLC on a C18 column, and were subjected to
amino acid sequencing (in the Biology Center, Technion, Israel).
3. Results
3.1. E¡ects of nucleotides on [3H]ryanodine binding to brain
microsomes
Fig. 1 shows that ATP is an activator of ryanodine binding
to sheep brain ryanodine receptors. Half-maximal stimulation
was obtained at about 0.3 mM, and maximal stimulation (of
about 2-fold) at 1 mM ATP. The degree of stimulation was
decreased at higher ATP concentrations (see also Table 1).
The frank inhibition of ryanodine binding by ATP concentra-
tions above 1 mM that has been seen in some other studies
[11,18] could be due to di¡erences in assay conditions, such as
the presence of 1 mM Mg2 in the assay medium, or to spe-
cies di¡erences in relative RyR isoform distributions. The
ability of ATP to stimulate ryanodine binding decreases as
the binding comes near its maximal level. Increasing the con-
centration of NaCl enhances ryanodine binding, and mark-
edly decreases the extent of stimulation by ATP (Table 1). As
a result, 0.5 M NaCl was used throughout these studies to
optimize measurements in the relevant experiments.
Fig. 2 shows the binding of [3H]ryanodine as a function of
its concentration (in 0.5 M NaCl), and in the absence and the
presence of 0.5 mM ATP. ATP increased the ryanodine bind-
ing a⁄nity, decreasing the KD about 3-fold, from 54 þ 6 nM
(n = 3) to 19 þ 5 nM (n = 2, means þ S.D.). Thus, the increase
in ryanodine binding produced by ATP appears to be attrib-
utable to increased a⁄nity of the receptor for ryanodine. Ta-
ble 2 shows that in the dark the photoreactive ATP analog,
3P-O-(4-benzoyl)benzoyl adenosine triphosphate (Bz2ATP),
acts like ATP to increase the binding of ryanodine to brain
microsomes. On photoactivation, very low (WM) concentra-
tions of Bz2ATP stimulated ryanodine binding, suggesting
that photoactivated Bz2ATP binds irreversibly to one or
more ATP binding sites. The e¡ect of various nucleotides
on ryanodine binding is presented in Table 3. The relative
stimulation of ryanodine binding decreases in the following
order of e¡ectiveness: Bz2ATPsATPsADPsAMPs
AMP-PNPvGTP, while cAMP had no e¡ect. This nucleotide
speci¢city is similar to that of the skeletal muscle RyR ATP
binding site [17].
3.2. Identi¢cation of ryanodine receptor isoforms and dynein
Fig. 3A shows the protein pro¢les of skeletal muscle SR,
cardiac SR and of brain microsomal preparation. Three high
MW protein bands are present, all near the expected position
of RyR proteins (these are labeled 1, 2 and 3). The major
band (band 3) does not correspond to the type-1 RyR of
skeletal muscle SR, which has an apparent mass on SDS-
PAGE of 460 kDa, nor does it correspond to the skeletal
muscle RyR degradation product of 375 kDa. Band 2 corre-
sponds to the cardiac type-2 RyR (440 kDa on SDS-PAGE),
and its identity is con¢rmed by its cross-reactivity with anti-
Fig. 1. Stimulation of ryanodine binding by ATP. Ryanodine bind-
ing to brain microsomes (2.5 mg/ml) was assayed as described in
Section 2 in the presence of 0.5 M NaCl, 10 nM ryanodine, 50 WM
free Ca2 (calculated as in [23]) and the indicated concentrations of
ATP.
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type-2 RyR antibodies (Fig. 3). Band 1 does not cross-react
with either of the anti-RyR antibodies, and it has no ATP
binding site (Fig. 3A and B). To determine whether band 3
(420 kDa) represented an additional RyR isoform (e.g. the
type-3 protein), or was a distinct protein we used di¡erent
antibodies. Anti-RyR-3 antibodies are not yet commercially
available. An anti-RyR antibody kindly supplied by V. Sor-
rentino failed to react speci¢cally with RyR. To identify this
protein band, brain microsomes were subjected to SDS-PAGE
and band 3 was cut of the gel and subjected to amino acid
sequencing. After digestion by endoproteinase Lys C, peptides
were separated by reverse phase HPLC and a selected peptide
was sequenced. We obtained a sequence of 18 amino acids
with 100% identity to the sequence of the following fragment
of rat brain cytosolic dynein heavy chain [27], part of the
mechanochemical ATPase that powers the tra⁄c of organelles
along microtubules [28]:
Residue no.: 4397 4414
K R T V E N I K D P L F R F F E R E
3.3. Bz2ATP labeling of brain microsomal membrane proteins
We used the photoreactive ATP analogue, Bz2ATP, to label
the ATP binding sites in brain microsomes. Fig. 3B shows
that irradiation of brain microsomes with [K-32P]-Bz2ATP re-
sulted in covalent binding of the label to several membrane
proteins, including two high MW proteins corresponding to
band 2 and band 3 (440 and 420 kDa, respectively). The
labeling of both protein bands by [K-32P]-Bz2ATP was pre-
vented in the presence of excess of ATP or ADP (data not
shown). The 440 kDa polypeptide which was labeled with
[K-32P]-Bz2ATP cross-reacts with both monoclonal anti-skel-
etal muscle and anti-cardiac RyR antibodies (Fig. 3C). How-
ever, the 420 kDa protein band is labeled much more inten-
sively with [K-32P]-Bz2ATP, and it cross-reacts with anti-
dynein antibodies. The same anti-dynein antibodies also
cross-react with a 420 kDa protein band in cardiac but not
in skeletal muscle SR. In skeletal muscle SR, there was weak
cross-reactivity of anti-dynein antibodies with two bands cor-
responding to the type-1 RyR and its proteolytic fragment. It
should be noted that we found that dynein was retained in
several rats and sheep brain microsomal preparations, even
after puri¢cation by sucrose density gradient centrifugation.
Fig. 2. The in£uence of ATP on the a⁄nity of the ryanodine binding site. A: The binding of [3H]ryanodine was assayed as described in Section
2 in the presence of 0.5 M NaCl and 50 WM free Ca2 with (a) or without (b) 0.5 mM ATP. B: Scatchard plot analysis (KD = 57 and 13 nM,
Bmax = 170 and 150 fmol/mg protein) in the absence and the presence of ATP, respectively.
Fig. 3. Electrophoretic pro¢le, immunoreactivity and [K-32P]-Bz2ATP labeling of skeletal muscle SR, cardiac SR and brain microsomes. Brain
microsomes (BM), skeletal SR (SSR) and cardiac SR (CSR) membranes were labeled with 1 WM [K-32P]-Bz2ATP and subjected to SDS-PAGE
in 3^6% (w/v) acrylamide followed by Coomassie blue staining (A), autoradiography (B) or immunoblot analysis (C). Western blotting was car-
ried out as described in Section 2 using anti-skeletal muscle RyR (1:500), anti-dynein (1:100) or anti-cardiac muscle RyR (1:1000) antibodies,
followed by HRP-conjugated anti-mouse or anti-rabbit antibodies as appropriate, and ECL detection. The skeletal muscle type-1 RyR protein
band is labeled in the Coomassie-stained gel (A) and in the anti-RyR-1 immunoblot (C). Note labeling of this band in SSR lane in (B). The
open arrow indicates the RyR-1 proteolytic fragment that is also labeled by [K-32P]-Bz2ATP. In the BM lane in (A), three high MW Coomas-
sie-stained bands are labeled (1^3), and in the BM lane in (B) the ¢lled arrow indicates dynein heavy chains (labeled as dynein in C).
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The concentration dependence of [K-32P]-Bz2ATP binding
to skeletal and cardiac muscle RyRs, and to the brain 440
kDa (RyR-2) and 420 kDa (dynein heavy chain) protein
bands, is presented in Fig. 4. The results illustrate how the
brain 420 kDa protein band, even with 10-fold lower Bz2ATP
concentrations, was much more intensively labeled than the
skeletal, cardiac or brain RyRs. This protein band was again
recognized by anti-dynein antibody, con¢rming that it repre-
sents dynein heavy chain (Fig. 3C). The labeling of each pro-
tein band relative to the amount of protein was: 8.7 þ 1.6
(n = 6), 2.0 þ 0.6 (n = 3), 2.1 þ 0.82 (n = 6) and 1.0 (n = 6) for
dynein, and the brain microsomal membrane RyR, cardiac
SR RyR and skeletal muscle SR RyR, respectively
(means þ S.D., n = no. of experiments, all normalized to skel-
etal muscle). Our attempt to locate the RyR ATP binding
site(s) more precisely in the protein primary sequence by lim-
ited proteolysis and microsequencing was unsuccessful be-
cause the very limited amount of RyR protein in sheep brain.
It should be noted that a potential ATP binding site(s) has not
yet mapped in the primary sequence of the more abundant
skeletal or cardiac RyR.
4. Discussion
4.1. Identi¢cation of a sheep brain RyR and brain dynein
We used photoa⁄nity labeling with [K-32P]-Bz2ATP as a
tool to identify and characterize the ATP regulatory site of
sheep brain RyR(s)/Ca2-release channel(s). However, a dom-
inant ATP binding protein band of 420 kDa is also present in
the brain microsomal fraction, and depending on the SDS-
PAGE conditions it co-migrates with a 440 kDa RyR. This
420 kDa protein band was identi¢ed as the heavy chain of
dynein based on: (a) interaction with speci¢c anti-dynein anti-
body (Fig. 3), (b) amino acid sequence of an 18 amino acid
peptide showing complete identity to a sequence of rat brain
dynein [27], and (c) over 1000-fold higher a⁄nity for ATP in
comparison to cardiac and skeletal muscle RyRs, as demon-
strated by its labeling with the photoreactive ATP analogue
[K-32P]-Bz2ATP (Figs. 3 and 4). It is thus important to be
aware of the presence of dynein in brain microsomal fractions.
An attempt to remove dynein by several approaches, includ-
ing extraction with ATP [29] and UV irradiation in the pres-
ence of Mg2, ATP and vanadate [30], was ine¡ective in com-
pletely separating cytosolic dynein and brain microsomes. One
sensitive approach that did clearly distinguish between RyR
monomer and dynein heavy chain was the use of the photo-
reactive ATP analog, Bz2ATP. Dynein was found to be highly
labeled at 1000-fold lower [K-32P]-Bz2ATP concentrations
(sub-micromolar concentrations, Fig. 4) in comparison to
brain, cardiac or skeletal muscle RyRs. Amino acid sequence
of both cytoplasmic and axonemal dynein heavy chains con-
tains four ATP binding consensus sequences [31,32]. These
sites, however, have not been characterized in detail. Bio-
chemical analysis of Tetrahymena cilliary dynein has sug-
gested that only one site participates directly in ATP hydrol-
ysis [33]. A Michael’s constant (Km) for ATP hydrolysis
(about 1 WM) indicates on high-a⁄nity ATP binding site.
The higher a⁄nity determined in this study is expected be-
cause of the covalent binding nature of the photoreactive
Bz2ATP.
Following optimal separation by SDS-PAGE of the high
MW protein bands in the range of 420^460 kDa, and the
use of speci¢c anti-dynein, anti-cardiac RyR and anti-skeletal
muscle RyR antibodies, it is however clear that the 440 kDa
protein is a RyR monomer (Fig. 3), and the cross-reactivity of
this protein band with anti-RyR-2 antibody suggests that it is
Fig. 4. Concentration dependence of [K-32P]-Bz2ATP labeling of RyR and dynein. Skeletal (a) and cardiac muscle (R) SR membranes, and
brain microsomes (O, b) (50 Wg), were labeled with the indicated concentrations of [K-32P]-Bz2ATP and subjected to SDS-PAGE, autoradiogra-
phy and quantitative analysis of the autoradiograms as described in Section 2. The labeling intensity (relative to the maximal labeling of each
protein) of the RyR monomers of skeletal (a), cardiac (R) and brain (O), and of brain dynein heavy chains (b), is presented in A as a func-
tion of [K-32P]-Bz2ATP concentration. In B, the autoradiographs of the high MW protein bands (460, 440 and 420 kDa bands) obtained from
skeletal, cardiac and brain microsomal membranes, respectively, and used for the quantitative analysis, are shown. The double open-headed ar-
row indicates RyR-1 proteolytic fragment and the single open-headed arrow indicates dynein heavy chain in cardiac SR, which has high a⁄nity
for [K-32P]-Bz2ATP and cross-reacts with anti-dynein antibody (Fig. 3C). This experiment is representative of four similar experiments.
Table 1
E¡ect of NaCl concentration on the stimulation of ryanodine bind-
ing by ATP
ATP concentration (mM) Ryanodine bound % of control
0.5 M NaCl 1 M NaCl
None 100 100
1 190 þ 21 90 þ 10
2 170 þ 21 97 þ 8*
3 140 þ 17 76 þ 15
Ryanodine binding to brain microsomes (2.5 mg/ml) was assayed as
in Fig. 1 in 0.5 or 1.0 M NaCl, 20 mM MOPS, pH 7.4, 50 WM free
Ca2, in the absence and in the presence of the indicated ATP con-
centration. Control activity (100%) = 38 and 83 fmol/mg protein for
ryanodine binding assayed in 0.5 and 1 M NaCl, respectively.
Results are shown þ S.D. (apart from *, which is the mean þ range
of two determinations).
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a type-2 RyR. Our monoclonal anti-skeletal muscle antibody
does also recognize the 440 kDa protein band in both brain
microsomes and cardiac SR (Fig. 3), but the proteins are
highly homologous [9]. It has previously been shown that a
monoclonal antibody to skeletal RyR detected several RyR
fragments in rat brain microsomes after proteolysis [34]. We
can not rule out the presence of another RyR isoform that is
not recognized by anti-RyR-1 and anti-RyR-2 antibodies, for
example a sheep type-3 isoform. However, given the non-
availability of a speci¢c and highly reactive anti-RyR-3 anti-
body, we cannot at this stage demonstrate the existence of
RyR-3 in our brain microsomal preparations.
4.2. Characterization of the sheep brain RyR ATP binding site
The stimulatory e¡ect of ATP on single Ca2 channel ac-
tivity and ryanodine binding appears to be due to a direct
interaction of ATP with brain RyRs [10^12,18], but the pre-
cise mechanism by which nucleotides modulate the brain
RyR/Ca2-release channel is unknown. It does not necessarily
involve protein phosphorylation, as non-hydrolyzable ATP
derivatives are e¡ective. One possible mechanism is that
ATP (or other nucleotides) bind to the RyR and stabilize a
protein conformation, which has a higher binding a⁄nity for
ryanodine (Fig. 2). This may be related to an increased prob-
ability of the channel being open [12] and, in the simplest of
models, increased access for the ligand to its binding site.
Bz2ATP enhanced the binding of ryanodine by up to 3-fold
more than other nucleotides (see Table 3). This may suggest
that the nucleotide binding sites have a higher a⁄nity for
Bz2ATP than ATP. It has been previously shown that
Bz2ATP is more e¡ective than ATP in activating the ATP-
gated cation channel (purinergic receptors) [35^37]. This may
suggest the nucleotide binding site binds better the more hy-
drophobic nucleotide. The observations that the aromatically
substituted analog 2P,3P-trinitrophenyl-adenosine 5P-triphos-
phate binds better than ATP to (Na+K) ATPase [38] and
to the SR Ca2-ATPase [39] support the above suggestion.
Alternatively, ATP may bind to two or more nucleotide bind-
ing sites with di¡erent a⁄nities, where binding to the high-
a⁄nity site stimulates, and binding to the low-a⁄nity site
inhibits ryanodine binding (Fig. 1, Table 1 and [11,18]). The
greater stimulation of ryanodine binding by Bz2ATP may be
due to its interaction with a high-a⁄nity ‘stimulatory’, but not
with the low-a⁄nity ‘inhibitory’ nucleotide binding site, so
that overall no inhibition of ryanodine binding is obtained.
The biphasic e¡ect of ATP on ryanodine binding ^ stimula-
tion followed by inhibition with increased ATP concentrations
(Fig. 1 and [11,17]) ^ supports the suggestion that there are
two or more nucleotide binding sites in the RyR with di¡erent
a⁄nities and the produced e¡ects.
4.3. Are brain microsomal membranes associated with the
cytoskeleton via cytosolic dynein?
Brain dynein is a microtubule-activated ATPase that func-
tions as a molecular motor to transport membrane organelles
retrogradely in the axon [28]. The observation that dynein is
associated with a brain microsomal membrane fraction sug-
gests there may be a speci¢c dynein-mediated interaction be-
tween microsomal ER membranes and the cytoskeleton. In
this respect, the ¢nding that RyR-1 and RyR-3 contain a
cytoskeleton binding motif that could confer a structural
and functional association with voltage-dependent Ca2 chan-
nels in skeletal muscle is of considerable interest [40]. Neuro-
nal L-type voltage-dependent Ca2 channels and RyRs are
clearly functionally coupled [41], and it is possible that an
underlying molecular coupling may be partly mediated by
microtubules and/or their associated motor protein dynein.
An interaction between the membrane-associated cytoskeletal
protein ankyrin and the mouse T-lymphoma cell RyR has
been demonstrated [42]. Furthermore, the binding of kinesin
and cytoplasmic dynein to brain microsomal fraction has been
demonstrated and characterized [43]. Both motors exhibit sat-
uration binding to the vesicles (1^6 binding sites per vesicle)
and the binding is abolished by proteolysis of vesicle mem-
brane proteins [40]. These ¢ndings may have broad signi¢-
cance in neuronal cell function, and suggest that the possible
direct or indirect association of brain RyRs with cytoskeleton
proteins should be further investigated.
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Table 3







AMP 0.5 130 þ 14
2.0 160 þ 16
cAMP 0.5 86 þ 9
2.0 95 þ 7
ADP 0.5 140 þ 14
2.0 120 þ 9
ATP 0.5 150 þ 15
1.0 150 þ 3
AMP-PNP 0.5 110 þ 2
1.0 150 þ 11
Bz2ATP 0.5 230 þ 21
1.0 280 þ 29
GTP 0.5 99 þ 1
2.0 140 þ 17
[3H]ryanodine binding was assayed in 0.5 M NaCl using 10 nM rya-
nodine in the absence and in the presence of the indicated nucleo-
tide as described in Table 1. The free Ca2 concentration was 50 WM
in each case. Control activity for [3H]ryanodine binding (100%) was
between 38 to 100 fmol/mg protein. The results are averages of two
to ¢ve experiments þ S.D. n.d., not determined.
Table 2
E¡ect of photoactivation of Bz2ATP on ryanodine binding
Bz2ATP concentration (WM) [3H]ryanodine bound % of control









Brain microsomes (1 mg/ml) were incubated in 0.4 M NaCl, 0.5
mM EDTA, 50 mM MOPS (pH 7.4) and the indicated concentra-
tion of Bz2ATP for 3 min in the dark or exposed to ultraviolet light
(UV). The samples were then diluted 2-fold with a solution to bring
about ¢nal concentrations of 25 mM MOPS, pH 7.4, 0.5 M NaCl,
50 WM free Ca2 and 10 nM ryanodine, and assayed (in the dark)
for ryanodine binding as described in Table 1. The data are repre-
sentatives of two similar experiments.
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